Dr Jeff Sharman talks to ecancer about the ELEVATE-TN study following acalabrutinib with or without obinutuzumab versus obinutuzumab + chlorambucil in previously untreated CLL.
Dr Sharman begins by talking about the importance of BTK inhibitors in the management of chronic lymphocytic leukaemia.
He then goes on to discuss the methodology, explaining that the study was a three-armed, randomised clinical trial. One arm looked at obinutuzumab plus chlorambucil, the second looked at acalabrutinib alone, and the third looked at acalabrutinib plus obinutuzumab.
Dr Sharman concludes by saying that he believes this particular study has achieved it's goal, however, they will continue to follow the results with time as there's an interest in seeing any additional differences between acalabrutinib as monotherapy and acalabrutinib plus obinutuzumab.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
